The challenge of therapy development in leukodystrophies
Bridging the gap between scientific progress and clinical translation
Leukodystrophies are a group of rare genetic disorders that affect the white matter of the brain and often lead to severe neurological impairment. While scientific advances have improved our understanding of these conditions, major challenges remain in developing therapies that can be effectively delivered, meaningfully evaluated and ultimately translated into clinical practice. POLARIS was created to help bridge this gap.
Three research objectives, one shared vision
Integrating gene therapy, pharmacological strategies and treatment evaluation
POLARIS is structured around three complementary research objectives. Together, they create a translational framework that connects scientific discovery with therapeutic impact.
Gene therapy strategies
Developing innovative genetic correction approaches and brain-targeting delivery platforms for selected leukodystrophies.
Pharmacological therapy strategies
Building a complementary pipeline for small-molecule and biologic discovery, validation and optimisation.
Treatment evaluation
Aligning therapeutic development with clinically meaningful, patient-relevant and affordable outcomes.














